Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenishaw Regulatory News (RSW)

Share Price Information for Renishaw (RSW)

Share Price is delayed by 15 minutes
Get Live Data
5,390.00    -65.00 (-1.19%)
Bid:
5,410.00
Ask:
5,420.00
Spread: 10.00 (0.185%)
Market Cap: £3.92b
RSW Live PriceLast checked at - London Stock Exchange

Intraday Renishaw Share Chart

Trading Statement

24 Oct 2024 07:00

RNS Number : 3723J
Renishaw PLC
24 October 2024
 

Renishaw plc

Trading update

24 October 2024

 

 

Solid revenue and profit growth in mixed trading conditions

Renishaw plc, the global provider of manufacturing technologies, analytical instruments and medical devices, publishes this trading update for the three months ended 30 September 2024. It contains unaudited information that covers the first quarter of the financial year.

 

 

Trading activity

 

 

3 months to 30 September 2024

3 months to 30 September 2023

Change

 

 

 

 

Manufacturing technologies

£167.5m

£156.8m

+7%

Analytical instruments and medical devices

£6.4m

£7.7m

-16%

Total revenue

£173.9m

£164.5m

+6%

Total revenue at constant exchange rates1

£171.3m

£165.0m

+4%

 

 

 

Adjusted profit before tax2

£34.0m

£28.0m

+22%

Statutory profit before tax

£34.0m

£28.0m

+22%

 

 

Revenue was £173.9m, representing a 6% increase compared to the corresponding period last year at actual exchange rates, and a 4% increase at constant currency1. The Americas and EMEA regions saw increased demand compared to Q1 FY2024, whilst APAC was lower compared to a strong period last year, which was boosted by orders from the consumer electronics sector. 

 

In our Manufacturing technologies business, revenue in the period was 7% higher than the prior year at £167.5m. Sales of position encoders to the semiconductor manufacturing sector saw strong growth compared to a subdued prior year comparator. Our Additive Manufacturing products also grew strongly, reflecting the good order book carried into FY2025. Meanwhile, demand for Industrial Metrology products was lower than last year, primarily due to the strong prior period sales to consumer electronics manufacturers in APAC.

 

Revenue for our Analytical instruments and medical devices business was £6.4m, a decrease of 16% compared with £7.7m last year, primarily from phasing for our Spectroscopy products.

 

Adjusted and Statutory profit before tax2 for the first quarter of FY2025 both amounted to £34.0m (FY2024: £28.0m).

 

 

Financial position

 

The Group's balance sheet remains strong with net cash and cash equivalents and bank deposit balances of £276.1m on 30 September 2024 (30 June 2024: £217.8m).

 

 

Outlook

 

The first quarter of FY2025 has seen solid revenue and profit growth in mixed trading conditions, with subdued demand in some markets, offset by good growth elsewhere. Whilst Q1 sales of our encoder products to the semiconductor manufacturing sector have been stronger than last year, we remain cautious about demand from this market in the remainder of FY2025. 

 

We continue to pursue a range of growth opportunities and anticipate solid overall revenue growth this year in line with the Board's expectations. Alongside this we also remain focused on the careful management of costs and delivery of productivity improvements, which together will help drive progress towards our margin objectives.

The results for the half year ending 31 December 2024 will be released on 13 February 2025.

 

Will Lee

Allen Roberts

 

Chief Executive

Group Finance Director

 

 

24 October 2024

 

 

Renishaw plc

Registered office

New Mills, Wotton-under-Edge, Gloucestershire, GL12 8JR

Registered number

01106260

Telephone number

+44 (0) 1453 524524

Website

www.renishaw.com

 

 

 

Notes

 

1. Revenue at constant exchange rates is defined as revenue recalculated using the same rates that were applicable to the previous year and excluding forward contract gains and losses.

2. There are no adjustments made between statutory and adjusted profit before tax.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTEAKEDALELFFA
Date   Source Headline
22nd Sep 20203:11 pmRNSReplacement Director/PDMR Shareholding
22nd Sep 20202:19 pmRNSDirector/PDMR Shareholding
8th Sep 20204:35 pmRNSDirector/PDMR Shareholding
1st Sep 20207:00 amRNSAnnual Financial Report
27th Aug 20207:00 amRNSDirector/PDMR Shareholding
17th Aug 20203:15 pmRNSDirector/PDMR Shareholding
13th Aug 20207:00 amRNSFinal Results
6th Aug 202010:00 amRNSNotice of Results
17th Jul 20208:06 amRNSTrading Statement
26th Jun 20201:08 pmRNSDirector/PDMR Shareholding
24th Jun 20203:35 pmRNSDirector/PDMR Shareholding
22nd Jun 20204:17 pmRNSDirector/PDMR Shareholding
10th Jun 20202:00 pmRNSDirector/PDMR Shareholding
5th Jun 20207:00 amRNS2020 Final Dividend
12th May 20207:00 amRNSTrading Statement
4th May 202012:00 pmRNSDisclosure of Rights Attached to Equity Shares
2nd Apr 20204:30 pmRNSStatement re 2019 AGM resolution votes
25th Mar 20204:28 pmRNSStatement re Interim dividend
6th Mar 20209:36 amRNSDirector/PDMR Shareholding
27th Feb 20204:47 pmRNSStatement re Interim dividend
30th Jan 20207:00 amRNSHalf-year Report
29th Jan 20205:45 pmRNSChange in Director's Responsibilities
20th Jan 202012:00 pmRNSNotice of Half-year Results
17th Jan 20209:47 amRNSHolding(s) in Company
24th Oct 20193:37 pmRNSResult of AGM
15th Oct 20197:00 amRNSTrading Statement
30th Aug 20193:00 pmRNSPurchase of Shares by Profit Share Trust
21st Aug 20197:00 amRNSAnnual Financial Report
1st Aug 20197:00 amRNSFinal Results
16th Jul 20193:00 pmRNSNotice of Results
25th Jun 20197:00 amRNSDirectorate Change
14th May 201910:00 amRNSDirector Declaration
14th May 20197:00 amRNSTrading Statement
27th Mar 201911:36 amRNSDirector/PDMR Shareholding
22nd Mar 20199:48 amRNSDirector/PDMR Shareholding
21st Mar 20197:00 amRNSTrading Statement
12th Mar 20194:00 pmRNSNotice of Investor Day
31st Jan 20197:00 amRNSHalf-year Report
15th Jan 20193:00 pmRNSNotice of Half-year Results
19th Dec 201810:07 amRNSDirector/PDMR Shareholding
29th Oct 20189:56 amRNSDirector/PDMR Shareholding
23rd Oct 201810:02 amRNSDirector/PDMR Shareholding
22nd Oct 201810:43 amRNSDirector/PDMR Shareholding
18th Oct 20184:02 pmRNSResult of AGM
18th Oct 20187:00 amRNSTrading Statement
23rd Aug 20182:00 pmRNSPurchase of Shares by Profit Share Trust
21st Aug 20187:00 amRNSAnnual Financial Report
3rd Aug 201812:00 pmRNSDirector/PDMR Shareholding
2nd Aug 20183:00 pmRNSDirector Declaration
26th Jul 20187:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.